Latest News
A National Institute on Aging senior investigator breaks down amyloid trials: what went wrong and what must come next.
Immune cells undergo non-inherited genetic changes that are associated with higher Alzheimer’s risk.
Brightfocus supports a groundbreaking $28M investment by the Canadian Institutes of Health Research to bolster early-career health researchers from historically under-recognized groups.
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
A new study asks the question: what if we could reverse the damage caused by Alzheimer’s disease-related proteins like tau? Learn more.
Newly released research portfolios highlight the 276 biomedical research projects funded by BrightFocus Foundation across 16 countries to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
The anti-amyloid therapy will go off the market later this year.
In This Issue:
- Current Research: Could Vision Lost to Glaucoma Be Restored?
- President’s Corner
- A BrightFocus Glaucoma Chat with Dr. Nazlee Zebardast
- First Look at Upcoming Research
- And more!
In this Issue
- President’s Corner
- New Blood Test Detects Unique Biomarker for Alzheimer’s
- Researcher Spotlight: Kevin Beier, PhD
- Medications That Can Mimic Dementia
- Help Fight Alzheimer’s Through a Donor Advised Fund
January is Glaucoma Awareness Month, and BrightFocus Foundation is pleased to announce the 2024 schedule of Glaucoma Chats, free, accessible and interactive audio podcast conversations with leading glaucoma specialists and eye care professionals.
